Well, we’ve made it to the final day of this year’s virtual J.P. Morgan Healthcare Conference. I’m nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. What’s been your takeaway from the virtual conference? Let me know at [email protected].
And as we head toward the end of a busy week, I wanted to introduce you all to the newest member of the team, Allison DeAngelis! Say hi via email at [email protected] and follow her on Twitter at @ADeAngelis_bio.
Today in healthcare news: We read through Sana Biotechnology’s S-1 so you don’t have to, Ro’s getting into in-home, rapid coronavirus testing, and why one biotech VC predicts microbiome companies will take off in 2021.
One of biotech’s most valuable startups just filed to go public. Here are 5 crucial takeaways from Sana’s 271-page filing.
- Sana Biotechnology has filed to go public.
- The secretive Seattle-based biotech has raised $US705.5 million since it was founded in July 2018.
- We dug through its 271-page filing to unearth five key details on Sana’s financials, strategy, and future.
$US1.5 billion digital-health startup Ro wants to be your online doctor. Here’s how its coronavirus response rooted in rapid at-home testing fits into the new unicorn’s long-term strategy.
- Ro, the direct-to-consumer digital health startup, announced Wednesday that it will teaming up with computer-vision startup Gauss to offer at-home rapid COVID-19 antigen tests.
- The partnership will start once Gauss’s test gets an emergency use authorization from the FDA.
- The news comes roughly a month after Ro announced it was acquiring at-home blood-testing startup Workpath, further indicating the startup’s ambitions to grow well beyond its roots in mail-order prescriptions for hair loss or erectile dysfunction.
A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021
- A top healthcare VC predicted microbiome drugs would rebound in 2021 as part of Business Insider’s year-end roundup of healthcare predictions.
- Though the biotech industry’s infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors’ interests.
- More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike.
More stories we’re reading:
- Silicon Valley billionaire investor Vinod Khosla said involving industry insiders in Pfizer and BioNTech’s vaccine early in development ‘would have slowed down’ progress (Business Insider)
- Is it ethical to get vaccinated before your turn? One bioethicist argues yes (Elemental)
- Fertility benefits company Progyny lost 85% of its business at the start of the pandemic. Here’s how its CEO is ramping up an aggressive growth strategy fuelled by acquisitions.(Business Insider)
- Talkspace is going public via SPAC in a deal that values the company at $US1.4 billion (Stat News)
- Walgreens is teasing a 200-person in-house startup that aims to improve healthcare. Here’s what to know. (Business Insider)
- SCOOP: Trump’s promise to send people $US200 drug discount cards isn’t happening, Medicare chief says (Business Insider)
Business Insider Emails & Alerts
Site highlights each day to your inbox.